Long-Term Safety and Clinical Outcomes of Livmarli in Patients With Alagille Syndrome (LEAP)
Latest Information Update: 30 May 2025
At a glance
- Drugs Maralixibat (Primary)
- Indications Alagille syndrome
- Focus Adverse reactions
- Acronyms LEAP
- Sponsors Mirum Pharmaceuticals
Most Recent Events
- 30 May 2025 Planned number of patients changed from 50 to 70.
- 30 May 2025 Planned End Date changed from 20 Sep 2028 to 20 Sep 2030.
- 09 Jan 2024 New trial record